Covaxin's clinical trials can resume in US as FDA lifts hold

The FDA's earlier decision, in April, to put on hold the trials was based on the US firm's decision to voluntarily implement a temporary pause in dosing participants of the jab, following the World Health Organisation's observations on Covaxin manufacturing plants in India.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/hWpYaNg
via IFTTT